The 10-year-old, who was born with NF1, has been participating in a trial at NIH that recently resulted in the first approval of a treatment.
Theresa Vargas, Washington Post: Local
Sat, 09/19/2020 - 8:00am
The 10-year-old, who was born with NF1, has been participating in a trial at NIH that recently resulted in the first approval of a treatment.